A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

Overactive Bladder Clinical Trial

— REDUCEOAB  

Official title:

A Prospective, Sham-Controlled, Safety and Efficacy Study of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Modulation and Digital Health System With Objective Confirmation of Nerve Activation for Use in Home by Subjects With Overactive Bladder Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05381116
• Other study ID #: AMHOAB2101
• Status: Terminated
• Phase: N/A
• Start date: April 14, 2022
• Est. completion date: July 1, 2023

Study information

• Verified date: May 2024
• Source: Avation Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-center, sham-controlled study comparing the safety and effectiveness of the self-adjusting, surgery-free, wearable Active System to a Sham System on adult Subjects diagnosed with OAB.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 125
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female and 18 years of age or older at the time of enrollment

2. Willing and capable of giving informed consent

3. Willing and able to comply with all Study-related requirements and procedures

4. Have been diagnosed or have symptoms of OAB for at least 3 months prior to enrollment

5. Have an average of 11 or more voiding events and/or 3 or more incontinent events per 24-hour period in a 3-Day Bladder Diary(a minimum of 30 voiding events over the 3 days measured by the Diary)

6. If currently on medications that may affect their OAB symptoms, is on a stable dose (no new, discontinued, or change in dose) of all prescribed medications for at least 4 weeks prior to enrollment or throughout the Study

7. Female Subjects of child-bearing potential must have a negative urine dip stick pregnancy test at baseline

Exclusion Criteria:

1. Has been diagnosed with incontinence due to neurogenic bladder(stroke, CNS tumors, Parkinson's etc.)

2. Have failed a third line treatment (PTNS, Botox or SNS) for their OAB because of lack of effectiveness within the 2 years prior to enrollment

3. Have evidence of an uncontrolled active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcomes, in the opinion of the Investigator

4. Has or had a significant untreated substance use disorder or polysubstance use disorder stemming from dependency-producing medications, alcohol, and/or illicit drugs less than 6 months prior to enrollment

5. Are planning to or have scheduled a surgery, for any condition, that would require catheterization, or a prolonged hospital stay and affect the ability to ambulate, use the toilet, or complete Therapy during the first 12 weeks of the Study

6. Has symptoms of, been diagnosed, or being actively treated for benign prostatic hyperplasia or prostate cancer (weak stream, straining, hesitancy, or intermittency)

7. Have a pacemaker or implanted defibrillator

8. Has a neurological disorder that affects the bladder or a diagnosis of interstitial cystitis, radiation cystitis, or fistulas

9. Incontinence due to stress-predominant mixed urinary incontinence (greater that 60% of the time)or being actively treated for stress urinary incontinence(Diagnosed or by review of the Baseline 3-Day Bladder Diary)

10. Has been diagnosed with or has symptoms of polyuria (>2500 cc urine output per day)

11. Has urinary retention or incomplete bladder emptying

12. Have a documented current or reoccurring Urinary Tract Infection (3 or more in the months prior to enrollment)

13. Have had Botox treatment for their OAB in the previous 8 months

14. Have used TENS anywhere on the body within the last year for any reason or anticipated use of TENS within 12 weeks of enrollment in pelvic region, back or legs for any reason

15. Had PTNS treatment for OAB within 6 months prior to enrollment.

16. Use of investigational drug/device Therapy, for any reason, within past 12 weeks

17. Current use or implantation of an implanted device for treatment of their OAB or incontinence (including but not limited to sacral nerve stimulators)

18. Participation in another clinical Study during the term of the Study

19. Pregnant or planning to become pregnant during the Study. Female Subjects of childbearing potential who become pregnant during the Study will be withdrawn from the Study and will be asked to sign a separate pregnancy consent form to allow the Investigator and Sponsor to follow up on the Subject's pregnancy and outcome

20. Has scar tissue, metal, or another implant or a large tattoo that might interfere with Therapy

21. Has a neurological disorder that causes abnormal sensations in the lower leg (loss of sensation or allodynia)

22. Has a skin condition, for example allergic reaction, rash or open wounds, in the area of where the Therapy Garment will be placed

Related Conditions & MeSH terms

• Overactive Bladder
• Urge Incontinence
• Urinary Bladder, Overactive
• Urinary Incontinence, Urge
• Urinary Urge Incontinence

Intervention

Device:
• Avation System
Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
• Sham Avation System
Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.

Locations

Country	Name	City	State
United States	Ochsner Medical Center	New Orleans	Louisiana
United States	Women's Health Institute	Oak Lawn	Illinois
United States	Flourish Research	San Antonio	Texas
United States	Regional Urology	Shreveport	Louisiana
United States	Eclipse Clinical Research	Tucson	Arizona
United States	Tranquil Medical Rsearch	Webster	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Avation Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Open-Label Phase Endpoints	During the Open-Label Phase, efficacy endpoints for enrolled Subjects that meet the inclusion criteria for average voids per day (frequency): a Subject that achieves a 50% or greater reduction, from baseline (Visit 1) in average voids per day relative to an upper normal limit of an average of 8 voids per day, or for enrolled Subjects that meet the inclusion criteria for incontinence events per day: a Subject that achieves a 50% or greater reduction from baseline (Visit 1) to in average incontinence events (IE) per day, except that Subjects initially enrolled in the Sham Arm will convert to Active Therapy (3x per week for 12 weeks followed by at least 1x per week for the remainder of the Study) and endpoints will be measured against their baseline (Visit 1) diary.; .	Length of Study, 24 months
Primary	The proportion of Subjects with a successful response	The proportion of Subjects with a successful response, where success is defined as: For enrolled Subjects that meet the inclusion criteria for average voids per day (frequency): a Subject that achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 4), in average voids per day relative to an upper normal limit of an average of 8 voids per day, or; For enrolled Subjects that meet the inclusion criteria for incontinence events per day: a Subject that achieves a 50% or greater reduction from baseline (Visit 1) to Week 12 (Visit 4) in average incontinence events (IE) per day.	Blinded Lead-In Portion of Study,12 Weeks
Secondary	Quality of Life Endpoints: Questionnaires	Evaluation of the Subject Quality of Life questionnaires used throughout the duration of the trial.	Length of Study, 24 months